RNA Modification in Metabolism

Abstract

Epigenetic regulation in disease development has been witnessed within this decade. RNA methylation is the predominant form of epigenetic regulation, and the most prevalent modification in RNA is N6-methyladenosine (m⁶A). Recently, RNA modification has emerged as a potential target for disease treatment. RNA modification is a posttranscriptional gene expression regulation that is involved in both physiological and pathological processes. Evidence suggests that m⁶A methylation significantly affects RNA metabolism, and its abnormal changes have been observed in a variety of diseases. Metabolic diseases are a series of diseases caused by abnormal metabolic processes of the body, the common metabolic diseases include diabetes mellitus, obesity, and nonalcoholic fatty liver disease, etc.; although the pathogenesis of these diseases differs from each other to the current understanding, most recent studies suggested pivotal role m⁶A in modulating these metabolic diseases, and m⁶A-based drug development has been on the agenda. This paper reviewed recent understanding of RNA modification in metabolic diseases, hoping to provide systematic information for those in this area.

Keywords

epigenomics / metabolic diseases / N ⁶-methyladenosine / RNA modifications

References

[1] Wu J., Wang K., Wang X., Pang Y., and Jiang C., “The Role of the Gut Microbiome and Its Metabolites in Metabolic Diseases,” Protein Cell 12, no. 5 (2021): 360–373.

[2] Li D., Li Y., Yang S., Lu J., Jin X., and Wu M., “Diet-gut Microbiota-epigenetics in Metabolic Diseases: From Mechanisms to Therapeutics,” Biomedicine & Pharmacotherapy 153 (2022): 113290.

[3] Zhao G. N., Tian Z. W., Tian T. et al., “TMBIM1 is an Inhibitor of Adipogenesis and Its Depletion Promotes Adipocyte Hyperplasia and Improves Obesity-related Metabolic Disease,” Cell Metabolism 33, no. 8 (2021): 1640–1654.e8.

[4] Cheng C., Yu F., Yuan G., and Jia J., “Update on N6-methyladenosine Methylation in Obesity-related Diseases,” Obesity (Silver Spring) 32, no. 2 (2024): 240–251.

[5] Blériot C., Dalmas E., Ginhoux F., and Venteclef N., “Inflammatory and Immune Etiology of Type 2 Diabetes,” Trends in Immunology 44, no. 2 (2023): 101–109.

[6] Charles-Messance H., Mitchelson K. A. J., Castro E. D. M., Sheedy F. J., and Roche H. M., “Regulating Metabolic Inflammation by Nutritional Modulation,” Journal of Allergy and Clinical Immunology 146, no. 4 (2020): 706–720.

[7] Rohm T. V., Meier D. T., Olefsky J. M., and Donath M. Y., “Inflammation in Obesity, Diabetes, and Related Disorders,” Immunity 55, no. 1 (2022): 31–55.

[8] Valenzuela-Vallejo L., Guatibonza-García V., and Mantzoros C. S., “Recent Guidelines for Non-Alcoholic Fatty Liver Disease (NAFLD)/Fatty Liver Disease (FLD): Are They Already Outdated and in Need of Supplementation?,” Metabolism 136 (2022): 155248.

[9] A. S. Sidney 4th, M. Emma, and N. Mazen, “Review Article: Role of Glucagon-Like Peptide-1 Receptor Agonists in Non-alcoholic Steatohepatitis, Obesity and Diabetes-what Hepatologists Need to Know,” Alimentary Pharmacology & Therapeutics 55, no. 8 (2022): 944–959.

[10] Huttasch M., Roden M., and Kahl S., “Obesity and MASLD: Is Weight Loss the (only) Key to Treat Metabolic Liver Disease?,” Metabolism 157 (2024): 155937.

[11] Oh A. R., Jeong Y., Yu J. et al., “Hepatocyte Kctd17 Inhibition Ameliorates Glucose Intolerance and Hepatic Steatosis Caused by Obesity-induced Chrebp Stabilization,” Gastroenterology 164, no. 3 (2023): 439–453.

[12] DeMarsilis A., Reddy N., Boutari C. et al., “Pharmacotherapy of Type 2 Diabetes: An Update and Future Directions,” Metabolism 137 (2022): 155332.

[13] Goldenberg R. M., Gilbert J. D., Manjoo P., Pedersen S. D., Woo V. C., and Lovshin J. A., “Management of Type 2 Diabetes, Obesity, or Nonalcoholic Steatohepatitis With High-dose GLP-1 Receptor Agonists and GLP-1 Receptor-based co-agonists,” Obesity Reviews 25, no. 3 (2024): e13663.

[14] Wu Y. L., Lin Z. J., Li C. C. et al., “Epigenetic Regulation in Metabolic Diseases: Mechanisms and Advances in Clinical Study,” Signal Transduct Target Therapy 8, no. 1 (2023): 98.

[15] Yang Y., Cai J., Yang X. et al., “Dysregulated m6A Modification Promotes Lipogenesis and Development of Non-alcoholic Fatty Liver Disease and Hepatocellular Carcinoma,” Molecular Therapy 30, no. 6 (2022): 2342–2353.

[16] Song B., Zeng Y., Cao Y. et al., “Emerging Role of METTL3 in Inflammatory Diseases: Mechanisms and Therapeutic Applications,” Frontiers in immunology 14 (2023): 1221609.

[17] Yang Z., Yu G. L., Zhu X., Peng T. H., and Lv Y. C., “Critical Roles of FTO-mediated mRNA m6A Demethylation in Regulating Adipogenesis and Lipid Metabolism: Implications in Lipid Metabolic Disorders,” Genes Dis 9, no. 1 (2022): 51–61.

[18] Shi H., Wei J., and He C., “Where, When, and How: Context-Dependent Functions of RNA Methylation Writers, Readers, and Erasers,” Molecular Cell 74, no. 4 (2019): 640–650.

[19] Chen F., Chen Z., Guan T. et al., “N(6) - Methyladenosine Regulates mRNA Stability and Translation Efficiency of KRT7 to Promote Breast Cancer Lung Metastasis,” Cancer Research 81, no. 11 (2021): 2847–2860.

[20] Liu C., Yu M., Wang M. et al., “PCAF-mediated Acetylation of METTL3 Impairs mRNA Translation Efficiency in Response to Oxidative Stress,” Science China Life Sciences 67, no. 10 (2024): 2157–2168.

[21] Regué L., Zhao L., Ji F., Wang H., Avruch J., and Dai N., “RNA m6A Reader IMP2/IGF2BP2 Promotes Pancreatic β-cell Proliferation and Insulin Secretion by Enhancing PDX1 Expression,” Molecular Metabolism 48 (2021): 101209.

[22] Yang K., Sun J., Zhang Z., Xiao M., Ren D., and Liu S. M., “Reduction of mRNA M(6)A Associates With Glucose Metabolism via YTHDC1 in human and Mice,” Diabetes Research and Clinical Practice 198 (2023): 110607.

[23] Li X., Yang Y., Li Z., Wang Y., Qiao J., and Chen Z., “Deficiency of WTAP in Islet Beta Cells Results in Beta Cell Failure and Diabetes in Mice,” Diabetologia 66, no. 6 (2023): 1084–1096.

[24] Kato M. and Natarajan R., “Epigenetics and Epigenomics in Diabetic Kidney Disease and Metabolic Memory,” Nature Reviews Nephrology 15, no. 6 (2019): 327–345.

[25] Wang M. K., Gao C. C., and Yang Y. G., “Emerging Roles of RNA Methylation in Development,” Accounts of Chemical Research 56, no. 23 (2023): 3417–3427.

[26] Zhang W., Zhang S., Dong C. et al., “A Bibliometric Analysis of RNA Methylation in Diabetes Mellitus and Its Complications From 2002 to 2022,” Frontiers of Endocrinology (Lausanne) 13 (2022): 997034.

[27] Klungland A. and Dahl J. A., “Dynamic RNA Modifications in Disease,” Current Opinion in Genetics & Development 26 (2014): 47–52.

[28] Li S., Mechal W. Z., and Ouyang X., “RNA Modifications in the Progression of Liver Diseases: From Fatty Liver to Cancer,” Science China Life Sciences 67, no. 10 (2024): 2105–2119.

[29] Li Y., Huang H., Wu S., Zhou Y., Huang T., and Jiang J., “The Role of RNA m6A Modification in Cancer Glycolytic Reprogramming,” Current Gene Therapy 23, no. 1 (2023): 51–59.

[30] Cayir A., “RNA Modifications as Emerging Therapeutic Targets,” Wiley Interdisciplinary Reviews RNA 13, no. 4 (2022): e1702.

[31] Cheng C., Yu F., Yuan G., and Jia J., “Update on N6-methyladenosine Methylation in Obesity-related Diseases,” Obesity (Silver Spring) 32, no. 2 (2024): 240–251.

[32] Zhang L., Xu X., and Su X., “Modifications of Noncoding RNAs in Cancer and Their Therapeutic Implications,” Cell. Signalling 108 (2023): 110726.

[33] Xia X., Wang Y., and Zheng J. C., “Internal m7G Methylation: A Novel Epitranscriptomic Contributor in Brain Development and Diseases,” Mol Ther Nucleic Acids 31 (2023): 295–308.

[34] Roundtree I. A., Evans M. E., Pan T., and He C., “Dynamic RNA Modifications in Gene Expression Regulation,” Cell 169, no. 7 (2017): 1187–1200.

[35] YuYan, Y. W., “Regulatory Effect of N6-methyladenosine on Tumor Angiogenesis,” Frontiers in Immunology 15 (2024): 1453774.

[36] An Y. and Duan H., “The Role of m6A RNA Methylation in Cancer Metabolism,” Molecular Cancer 21, no. 1 (2022): 14.

[37] Fan S. and Hu Y., “Role of m6A Methylation in the Occurrence and Development of Heart Failure,” Frontiers in Cardiovascular Medicine 9 (2022): 892113.

[38] Tang Q., Li L., Wang Y. et al., “RNA Modifications in Cancer,” British Journal of Cancer 129, no. 2 (2023): 204–221.

[39] Zhuang H., Yu B., Tao D. et al., “The Role of m6A Methylation in Therapy Resistance in Cancer,” Molecular cancer 22, no. 1 (2023): 91.

[40] Li L., Xia X., Yang T. et al., “RNA Methylation: A Potential Therapeutic Target in Autoimmune Disease,” International Reviews of Immunology 43, no. 3 (2024): 160–177.

[41] Liu J. and Jia G., “Methylation Modifications in Eukaryotic Messenger RNA,” Journal of Genetics and Genomics 41, no. 1 (2014): 21–33.

[42] Kumari R., Ranjan P., Suleiman Z. G. et al., “mRNA Modifications in Cardiovascular Biology and Disease: With a Focus on m6A Modification,” Cardiovascular Research 118, no. 7 (2022): 1680–1692.

[43] Jing F. Y., Zhou L. M., Ning Y. J., Wang X. J., and Zhu Y. M., “The Biological Function, Mechanism, and Clinical Significance of m6A RNA Modifications in Head and Neck Carcinoma: A Systematic Review,” Frontiers in Cell and Developmental Biology 9 (2021): 683254.

[44] Garbo S., Zwergel C., and Battistelli C., “m6A RNA Methylation and Beyond—The Epigenetic Machinery and Potential Treatment Options,” Drug Discovery Today 26, no. 11 (2021): 2559–2574.

[45] Huang Y., Xue Q., Chang J. et al., “M6A methylation Modification in Autoimmune Diseases, a Promising Treatment Strategy Based on Epigenetics,” Arthritis Research & Therapy 25, no. 1 (2023): 189.

[46] Du A., Li S., Zhou Y. et al., “M6A-mediated Upregulation of circMDK Promotes Tumorigenesis and Acts as a Nanotherapeutic Target in Hepatocellular Carcinoma,” Molecular cancer 21, no. 1 (2022): 109.

[47] Zhang L., Cheng Y., Xue Z. et al., “Sevoflurane Impairs m6A-mediated mRNA Translation and Leads to Fine Motor and Cognitive Deficits,” Cell Biology and Toxicology 38, no. 2 (2022): 347–369.

[48] Wang Y., Zou J., and Zhou H., “N6-methyladenine RNA Methylation Epigenetic Modification and Diabetic Microvascular Complications,” Frontiers of Endocrinology (Lausanne) 15 (2024): 1462146.

[49] Yin H., Zhang X., Yang P. et al., “RNA m6A Methylation Orchestrates Cancer Growth and Metastasis via Macrophage Reprogramming,” Nature Communications 12, no. 1 (2021): 1394.

[50] Jin S., Li M., Chang H. et al., “The m6A Demethylase ALKBH5 Promotes Tumor Progression by Inhibiting RIG-I Expression and Interferon Alpha Production Through the IKKϵ/TBK1/IRF3 Pathway in Head and Neck Squamous Cell Carcinoma,” Molecular cancer 21, no. 1 (2022): 97.

[51] Li Y., Zhang Y., Zhang T. et al., “Rna M(6) a Methylation Regulates Glycolysis of Beige Fat and Contributes to Systemic Metabolic Homeostasis,” Advanced Science (Weinh) 10, no. 25 (2023): e2300436.

[52] Zhang B., Jiang H., Dong Z., Sun A., and Ge J., “The Critical Roles of m6A Modification in Metabolic Abnormality and Cardiovascular Diseases,” Genes & Diseases 8, no. 6 (2020): 746–758.

[53] Wu Y., Zeng Y., Ren Y., Yu J., Zhang Q., and Xiao X., “Insights Into RNA N6-methyladenosine in Glucose and Lipid Metabolic Diseases and Their Therapeutic Strategies,” Endocrinology 165, no. 1 (2023): bqad170.

[54] Curtis E. M., Fuggle N. R., Cooper C., and Harvey N. C., “Epigenetic Regulation of Bone Mass,” Best Practice & Research. Clinical Endocrinology & Metabolism 36, no. 2 (2022): 101612.

[55] Han D. and Xu M. M., “RNA Modification in the Immune System,” Annual Review of Immunology 41 (2023): 73–98.

[56] Zhang Y., Lu L., and Li X., “Detection Technologies for RNA Modifications,” Experimental & Molecular Medicine 54, no. 10 (2022): 1601–1616.

[57] Wang M. K., Gao C. C., and Yang Y. G., “Emerging Roles of RNA Methylation in Development,” Accounts of Chemical Research 56, no. 23 (2023): 3417–3427.

[58] Wiener D. and Schwartz S., “The Epitranscriptome Beyond mA,” Nature Reviews Genetics 22, no. 2 (2021): 119–131.

[59] Song H., Zhang J., Liu B. et al., “Biological Roles of RNA m5C Modification and Its Implications in Cancer Immunotherapy,” Biomarker Research 10, no. 1 (2022): 15.

[60] Ilieva M. and Uchida S., “Epitranscriptomics in Fibroblasts and Fibrosis,” American Journal of Physiology. Cell Physiology 322, no. 6 (2022): C1110–C1116.

[61] Zhao Z., Yan W., and Weng X., “RNA Modifications Identification Based on Chemical Reactions,” Bioorganic & Medicinal Chemistry 111 (2024): 117861.

[62] Ye L., Yao X., Xu B. et al., “RNA Epigenetic Modifications in Ovarian Cancer: The Changes, Chances, and Challenges,” Wiley Interdisciplinary Review RNA 14, no. 5 (2023): e1784.

[63] Orsolic I., Carrier A., and Esteller M., “Genetic and Epigenetic Defects of the RNA Modification Machinery in Cancer,” Trends in Genetics 39, no. 1 (2023): 74–88.

[64] Yang B., Wang J. Q., Tan Y., Yuan R., Chen Z. S., and Zou C., “RNA Methylation and Cancer Treatment,” Pharmacological Research 174 (2021): 105937.

[65] Shinde H., Dudhate A., Kadam U. S., and Hong J. S., “RNA Methylation in Plants: An Overview,” Frontiers in Plant Science 14 (2023): 1132959.

[66] Han M., Sun H., Zhou Q. et al., “Effects of RNA Methylation on Tumor Angiogenesis and Cancer Progression,” Molecular cancer 22, no. 1 (2023): 198.

[67] Shafabakhsh R., Aghadavod E., Ghayour-Mobarhan M., Ferns G., and Asemi Z., “Role of Histone Modification and DNA Methylation in Signaling Pathways Involved in Diabetic Retinopathy,” Journal of Cellular Physiology 234, no. 6 (2019): 7839–7846.

[68] Qi Y. N., Liu Z., Hong L. L., Li P., and Ling Z. Q., “Methyltransferase-Like Proteins in Cancer Biology and Potential Therapeutic Targeting,” Journal of hematology & oncology 16, no. 1 (2023): 89.

[69] Gao Y. and Fang J., “RNA 5-methylcytosine Modification and Its Emerging Role as an Epitranscriptomic Mark,” RNA Biology 18, no. sup1 (2021): 117–127.

[70] Zhu X., Xia M., and Gao X., “Update on Genetics and Epigenetics in Metabolic Associated Fatty Liver Disease,” Therapeutic Advances in Endocrinology and Metabolism 13 (2022): 20420188221132138.

[71] Sun H., Li K., Liu C., and Yi C., “Regulation and Functions of Non-m(6)A mRNA Modifications,” Nature Reviews Molecular Cell Biology 24, no. 10 (2023): 714–731.

[72] Zou J., Liu H., Tan W. et al., “Dynamic Regulation and Key Roles of Ribonucleic Acid Methylation,” Frontiers of Cell Neuroscience 16 (2022): 1058083.

[73] Zou Y., Guo Z., Ge X. Y., and Qiu Y., “RNA Modifications in Pathogenic Viruses: Existence, Mechanism, and Impacts,” Microorganisms 12, no. 11 (2024): 2373.

[74] Sun H., Li K., Liu C., and Yi C., “Regulation and Functions of Non-mA mRNA Modifications,” Nature Reviews Molecular Cell Biology 24, no. 10 (2023): 714–731.

[75] Green M., Arora K., and Prakash S., “Microbial Medicine: Prebiotic and Probiotic Functional Foods to Target Obesity and Metabolic Syndrome,” International Journal of Molecular Sciences 21, no. 8 (2020): 2890.

[76] Moetlediwa M. T., Ramashia R., Pheiffer C., Titinchi S. J. J., Mazibuko-Mbeje S. E., and Jack B. U., “Therapeutic Effects of Curcumin Derivatives Against Obesity and Associated Metabolic Complications: A Review of in Vitro and in Vivo Studies,” International Journal of Molecular Sciences 24, no. 18 (2023): 14366.

[77] Berggren K. A., Schwartz R. E., Kleiner R. E., and Ploss A., “The Impact of Epitranscriptomic Modifications on Liver Disease,” Trends in Endocrinology and Metabolism 35, no. 4 (2024): 331–346.

[78] Liu Y., Z. Yuan, Wu R. et al., “mRNA m5C Controls Adipogenesis by Promoting CDKN1A mRNA Export and Translation,” RNA Biology 18, no. sup2 (2021): 711–721.

[79] Liu Y., Yang Y., Wu R. et al., “mRNA M(5)C Inhibits Adipogenesis and Promotes Myogenesis by Respectively Facilitating YBX2 and SMO mRNA Export in ALYREF-m(5)C Manner,” Cellular and Molecular Life Sciences 79, no. 9 (2022): 481.

[80] Benak D., Sevcikova A., Holzerova K., and Hlavackova M., “FTO in Health and Disease,” Frontiers in Cell and Developmental Biology 12 (2024): 1500394.

[81] Delaunay S., Helm M., and Frye M., “RNA Modifications in Physiology and Disease: Towards Clinical Applications,” Nature Reviews Genetics 25, no. 2 (2024): 104–122.

[82] Chen D., Gu X., Nurzat Y. et al., “Writers, Readers, and Erasers RNA Modifications and Drug Resistance in Cancer,” Molecular cancer 23, no. 1 (2024): 178.

[83] Reed J., Bain S., and Kanamarlapudi V., “A Review of Current Trends With Type 2 Diabetes Epidemiology, Aetiology, Pathogenesis, Treatments and Future Perspectives,” Diabetes, Metabolic Syndrome and Obesity 14 (2021): 3567–3602.

[84] Huda M. N., Kim M., and Bennett B. J., “Modulating the Microbiota as a Therapeutic Intervention for Type 2 Diabetes,” Frontiers of Endocrinology (Lausanne) 12 (2021): 632335.

[85] Zhang H., Gu Y., Gang Q., Huang J., Xiao Q., and Ha X., “N6-methyladenosine RNA Modification: An Emerging Molecule in Type 2 Diabetes Metabolism,” Frontiers of Endocrinology (Lausanne) 14 (2023): 1166756.

[86] Suárez R., Chapela S. P., Álvarez-Córdova L. et al., “Epigenetics in Obesity and Diabetes Mellitus: New Insights,” Nutrients 15, no. 4 (2023): 811.

[87] Li Y. L., Li L., Liu Y. H., Hu L. K., and Yan Y. X., “Identification of Metabolism-Related Proteins as Biomarkers of Insulin Resistance and Potential Mechanisms of M(6)A Modification,” Nutrients 15, no. 8 (2023): 1839.

[88] Song Y., Jiang Y., Shi L. et al., “Comprehensive Analysis of Key m5C Modification-related Genes in Type 2 Diabetes,” Frontiers in Genetics 13 (2022): 1015879.

[89] Wei S., Wang L., Evans P. C., and Xu S., “NAFLD and NASH: Etiology, Targets and Emerging Therapies,” Drug Discovery Today 29, no. 3 (2024): 103910.

[90] Targher G., Byrne C. D., and Tilg H., “NAFLD and Increased Risk of Cardiovascular Disease: Clinical Associations, Pathophysiological Mechanisms and Pharmacological Implications,” Gut 69, no. 9 (2020): 1691–1705.

[91] Gofton C., Upendran Y., Zheng M. H., and George J. M., “How Is It Different From NAFLD?,” Clinical and Molecular Hepatology 29, no. Suppl (2023): S17–S31.

[92] Li L., Sun Y., Li L. et al., “The Deficiency of ALKBH5 Contributes to Hepatic Lipid Deposition by Impairing VPS11-Dependent Autophagic Flux,” Febs Journal 291, no. 23 (2024): 5256–5275.

[93] He J., Xiao C., Li C., Yang F., and Du C., “Integrative Analysis of Bulk and Single-cell RNA Sequencing Data Reveals Distinct Subtypes of MAFLD Based on N1-methyladenosine Regulator Expression,” Liver Research 7, no. 2 (2023): 145–155.

[94] Aggeletopoulou I., Kalafateli M., Tsounis E. P., and Triantos C., “Epigenetic Regulation in Lean Nonalcoholic Fatty Liver Disease,” International Journal of Molecular Sciences 24, no. 16 (2023): 12864.

[95] Zheng W., Guo J., and Liu Z. S., “Effects of Metabolic Memory on Inflammation and Fibrosis Associated With Diabetic Kidney Disease: An Epigenetic Perspective,” Clinical Epigenetics 13, no. 1 (2021): 87.

[96] Yang Y., Lu J., Liu Y. et al., “Improvement of MASLD and MASH by Suppression of Hepatic N-acetyltransferase 10,” Molecular Metabolism 89 (2024): 102030.

[97] Li S., Mechal W. Z., and Ouyang X., “RNA Modifications in the Progression of Liver Diseases: From Fatty Liver to Cancer,” Science China Life Sciences 67, no. 10 (2024): 2105–2119.

[98] Song Y., Jiang Y., Shi L. et al., “Comprehensive Analysis of Key m5C Modification-related Genes in Type 2 Diabetes,” Frontiers in Genetics 13 (2022): 1015879.

[99] Xiong X., Hou L., Park P. et al., “Genetic Drivers of M(6)A Methylation in human Brain, Lung, Heart and Muscle,” Nature Genetics 53, no. 8 (2021): 1156–1165.

[100] Deng X., Qing Y., Horne D., Huang H., and Chen J., “The Roles and Implications of RNA m6A Modification in Cancer,” Nature Reviews Clinical oncology 20, no. 8 (2023): 507–526.

[101] Jiang X., Liu B., Nie Z. et al., “The Role of m6A Modification in the Biological Functions and Diseases,” Signal Transduction and Targeted Therapy 6, no. 1 (2021): 74.

[102] Boulias K. and Greer E. L., “Biological Roles of Adenine Methylation in RNA,” Nature Reviews Genetics 24, no. 3 (2022): 143–160.

[103] Wei J., Yu X., Yang L. et al., “FTO Mediates LINE1 M(6)A Demethylation and Chromatin Regulation in mESCs and Mouse Development,” Science 376, no. 6596 (2022): 968–973.

[104] Wang Y., Wang, P. H. et al., “Epigenetic Modification of M(6)A Regulator Proteins in Cancer,” Molecular cancer 22, no. 1 (2023): 102.

[105] An Y. and Duan H., “The Role of m6A RNA Methylation in Cancer Metabolism,” Molecular cancer 21, no. 1 (2022): 14.

[106] Kan R. L., Chen J., and Sallam T., “Crosstalk Between Epitranscriptomic and Epigenetic Mechanisms in Gene Regulation,” Trends in Genetics 38, no. 2 (2021): 182–193.

[107] Yang Z., Cai Z., Yang C., Luo Z., and Bao X., “ALKBH5 regulates STAT3 Activity to Affect the Proliferation and Tumorigenicity of Osteosarcoma via an m6A-YTHDF2-dependent Manner,” EBioMedicine 80 (2022): 104019.

[108] Dubey P. K., Patil M., Singh S. et al., “Increased m6A-RNA Methylation and FTO Suppression Is Associated With Myocardial Inflammation and Dysfunction During Endotoxemia in Mice,” Molecular and Cellular Biochemistry 477, no. 1 (2022): 129–141.

[109] Hu J., Lin H., Wang C., Su Q., and Cao B., “METTL14-mediated RNA Methylation in Digestive System Tumors,” International Journal of Molecular Medicine 52, no. 3 (2023): 86.

[110] Perry R. P., Kelley D. E., Friderici K., and Rottman F., “The Methylated Constituents of L Cell Messenger RNA: Evidence for an Unusual Cluster at the 5’ terminus,” Cell 4, no. 4 (1975): 387–394.

[111] Desrosiers R., Friderici K., and Rottman F., “Identification of Methylated Nucleosides in Messenger RNA From Novikoff Hepatoma Cells,” PNAS 71, no. 10 (1974): 3971–3975.

[112] Jia G., Fu Y., Zhao X. et al., “N6-methyladenosine in Nuclear RNA Is a Major Substrate of the Obesity-Associated FTO,” Nature Chemical Biology 7, no. 12 (2011): 885–887.

[113] Wang Q., Fan X., Sheng Q. et al., “N6-methyladenosine Methylation in Kidney Injury,” Clin Epigenetics 15, no. 1 (2023): 170.

[114] Bu F. T., Wang H. Y., Xu C. et al., “The Role of m6A-associated Membraneless Organelles in the RNA Metabolism Processes and human Diseases,” Theranostics 14, no. 12 (2024): 4683–4700.

[115] Xue H., Ma Y., Guan K. et al., “The Role of m6A Methylation in Targeted Therapy Resistance in Lung Cancer,” The American Journal of Cancer Research 14, no. 6 (2024): 2994–3009.

[116] Yin R., Chang J., Li Y. et al., “Differential M(6)A RNA Landscapes Across Hematopoiesis Reveal a Role for IGF2BP2 in Preserving Hematopoietic Stem Cell Function,” Cell Stem Cell 29, no. 1 (2021): 149–159.e7.

[117] Wu Y., Xu X., Qi M. et al., “N(6)-methyladenosine Regulates Maternal RNA Maintenance in Oocytes and Timely RNA Decay During Mouse Maternal-to-zygotic Transition,” Nature Cell Biology 24, no. 6 (2022): 917–927.

[118] Li Y., Dou X., Liu J. et al., “Globally Reduced N(6)-methyladenosine (m(6)A) in C9ORF72-ALS/FTD Dysregulates RNA Metabolism and Contributes to Neurodegeneration,” Nature Neuroscience 26, no. 8 (2023): 1328–1338.

[119] Meyer K. D., Saletore Y., Zumbo P., Elemento O., Mason C. E., and Jaffrey S. R., “Comprehensive Analysis of mRNA Methylation Reveals Enrichment in 3’ UTRs and near Stop Codons,” Cell 149, no. 7 (2012): 1635–1646.

[120] Liu Y., Li J., Wang C. et al., “The m6A Writer KIAA1429 Regulates Photoaging Progression via MFAP4-dependent Collagen Synthesis,” BMC Biology 22, no. 1 (2024): 192.

[121] Jiang X., Liu B., Nie Z. et al., “The Role of m6A Modification in the Biological Functions and Diseases,” Signal Transduction Target Therapy 6, no. 1 (2021): 74.

[122] Zhang N., Ding C., Zuo Y., Peng Y., and Zuo L., “N6-methyladenosine and Neurological Diseases,” Molecular Neurobiology 59, no. 3 (2022): 1925–1937.

[123] McIntyre A. B. R., Gokhale N. S., Cerchitti L. et al., “Limits in the Detection of M(6)A Changes Using MeRIP/M(6)A-seq,” Scientific Reports 10, no. 1 (2020): 6590.

[124] Zhang M., Xiao Y., Jiang Z., and Yi C., “Quantifying M(6)A and Ψ Modifications in the Transcriptome via Chemical-Assisted Approaches,” Accounts of Chemical Research 56, no. 21 (2023): 2980–2991.

[125] Zhang W., Qian Y., and Jia G., “The Detection and Functions of RNA Modification M(6)A Based on M(6)A Writers and Erasers,” Journal of Biological Chemistry 297, no. 2 (2021): 100973.

[126] Wu L., Quan W., Zhang Y. et al., “Attenuated Duck Hepatitis A Virus Infection Is Associated with High mRNA Maintenance in Duckling Liver via m6A Modification,” Frontiers in Immunology 13 (2022): 839677.

[127] Du Y., Yuan Y., Xu L. et al., “Discovery of METTL3 Small Molecule Inhibitors by Virtual Screening of Natural Products,” Frontiers in pharmacology 13 (2022): 878135.

[128] Wang M., Liu J., Zhao Y. et al., “Upregulation of METTL14 Mediates the Elevation of PERP mRNA N Adenosine Methylation Promoting the Growth and Metastasis of Pancreatic Cancer,” Molecular Cancer 19, no. 1 (2020): 130.

[129] Sun D., Cai X., Shen F. et al., “Transcriptome-Wide m6A Methylome and m6A-Modified Gene Analysis in Asthma,” Frontiers in Cell and Developmental Biology 10 (2022): 799459.

[130] Dominissini D., Moshitch-Moshkovitz S., and Schwartzet S., “Topology of the human and Mouse m6A RNA Methylomes Revealed by m6A-seq,” Nature 485, no. 7397 (2012): 201–206.

[131] Ayyala D. N., Lin J., and Ouyang Z., “Differential RNA Methylation Using Multivariate Statistical Methods,” Brief Bioinformatics 23, no. 1 (2022): bbab309.

[132] Linder B., Grozhik A. V., Olarerin-George A. O., Meydan C., Mason C. E., and Jaffrey S. R., “Single-nucleotide-resolution Mapping of m6A and m6Am throughout the Transcriptome,” Nature Methods 12, no. 8 (2015): 767–772.

[133] Zhang Z., Chen L. Q., Zhao Y. et al., “Single-base Mapping of mA by an Antibody-independent Method,” Science Advances 5, no. 7 (2019): eaax0250.

[134] Meyer K. D., “DART-seq: An Antibody-free Method for Global mA Detection,” Nature Methods 16, no. 12 (2019): 1275–1280.

[135] Shu X., Cao J., Cheng M. et al., “A Metabolic Labeling Method Detects M(6)A Transcriptome-wide at Single Base Resolution,” Nature Chemical Biology 16, no. 8 (2020): 887–895.

[136] Hu L., Liu S., Peng Y. et al., “m(6)A RNA Modifications Are Measured at Single-base Resolution Across the Mammalian Transcriptome,” Nature Biotechnology 40, no. 8 (2022): 1210–1219.

[137] Liu C., Sun H., Yi Y. et al., “Absolute Quantification of Single-base M(6)A Methylation in the Mammalian Transcriptome Using GLORI,” Nature Biotechnology 41, no. 3 (2023): 355–366.

[138] Mao Z., Wang B., Zhang T., and Cui B., “The Roles of m6A Methylation in Cervical Cancer: Functions, Molecular Mechanisms, and Clinical Applications,” Cell death & disease 14, no. 11 (2023): 734.

[139] Feng X. and He C., “Mammalian DNA N(6)-methyladenosine: Challenges and New Insights,” Molecular Cell 83, no. 3 (2023): 343–351.

[140] Krusnauskas R., Stakaitis R., Steponaitis G., Almstrup K., and Vaitkiene P., “Identification and Comparison of m6A Modifications in Glioblastoma Non-coding RNAs With MeRIP-seq and Nanopore dRNA-seq,” Epigenetics 18, no. 1 (2023): 2163365.

[141] Petri B. J., Cave M. C., and Klinge C. M., “Changes in m6A in Steatotic Liver Disease,” Genes (Basel) 14, no. 8 (2023): 1653.

[142] Shang M., Qin J., Zhao B. et al., “Recent Advance in Sensitive Detection of Demethylase FTO,” Chembiochem (2024): e202400995.

[143] Guo L., Yang H., Zhou C., Shi Y., Huang L., and Zhang J., “N6-Methyladenosine RNA Modification in the Tumor Immune Microenvironment: Novel Implications for Immunotherapy,” Frontiers in Immunology 12 (2021): 773570.

[144] Gu C., Wu J., Zhang W. et al., “Immune Infiltration of Ulcerative Colitis and Detection of the m6A Subtype,” Journal of Immunology Research 2022 (2022): 7280977.

[145] He Y., Du X., Chen M., Han L., and Sun J., “Novel Insight Into the Functions of N(6)-Methyladenosine Modified lncRNAs in Cancers (Review),” International Journal of Oncology 61, no. 6 (2022): 152.

[146] Oerum S., Meynier V., Catala M., and Tisné C., “A Comprehensive Review of m6A/m6Am RNA Methyltransferase Structures,” Nucleic Acids Res. 49, no. 13 (2021): 7239–7255.

[147] Wang P., Doxtader K., and Nam Y., “Structural Basis for Cooperative Function of Mettl3 and Mettl14 Methyltransferases,” Molecular Cell 63, no. 2 (2016): 306–317.

[148] Truffinet F., Arco-Hierves A., Shalabi H. et al., “m(6)A RNA Methylation Controls Salivary Gland Epithelial Cell Function and Has a Protective Role in Sjögren’s Disease,” Annals of the Rheumatic Diseases (2024): ard–2024–226224.

[149] Shi H., Wei J., and He C., “Where, When, and How: Context-Dependent Functions of RNA Methylation Writers, Readers, and Erasers,” Molecular Cell 74, no. 4 (2019): 640–650.

[150] Song H., Song J., Cheng M. et al., “METTL3-mediated M(6)A RNA Methylation Promotes the Anti-tumour Immunity of Natural Killer Cells,” Nature Communications 12, no. 1 (2021): 5522.

[151] Chen J., Fang Y., Xu Y., and Sun H., “Role of m6A Modification in Female Infertility and Reproductive System Diseases,” International Journal of Biological Sciences 18, no. 9 (2022): 3592–3604.

[152] Wang Y., Li L., Li J. et al., “The Emerging Role of m6A Modification in Regulating the Immune System and Autoimmune Diseases,” Frontiers in Cell and Developmental Biology 9 (2021): 755691.

[153] Huang Q., Mo J., Liao Z., Chen X., and Zhang B., “The RNA M(6)A Writer WTAP in Diseases: Structure, Roles, and Mechanisms,” Cell Death & Disease 13, no. 10 (2022): 852.

[154] Song N., Cui K., Zhang K. et al., “The Role of m6A RNA Methylation in Cancer: Implication for Nature Products Anti-Cancer Research,” Frontiers in Pharmacology 13 (2022): 933332.

[155] Kaur S., Tam N. Y., McDonough M. A., Schofield C. J., and Aik W. S., “Mechanisms of Substrate Recognition and N6-methyladenosine Demethylation Revealed by Crystal Structures of ALKBH5-RNA Complexes,” Nucleic Acids Research 50, no. 7 (2022): 4148–4160.

[156] Azzam S. K., Alsafar H., and Sajini A. A., “FTO m6A Demethylase in Obesity and Cancer: Implications and Underlying Molecular Mechanisms,” International Journal of Molecular Sciences 23, no. 7 (2022): 3800.

[157] Ren S., Ji Y., Wang M. et al., “The m6A Demethylase FTO Promotes Keloid Formation by Up-regulating COL1A1,” Annals of Translational Medicine 11, no. 1 (2023): 15.

[158] Chen Y., Zhao Y., Chen J. et al., “ALKBH5 suppresses Malignancy of Hepatocellular Carcinoma via M(6)A-guided Epigenetic Inhibition of LYPD1,” Molecular Cancer 19, no. 1 (2020): 123.

[159] Huang M., Guo J., Liu L., Jin H., Chen X., and Zou J., “m6A demethylase FTO and Osteoporosis: Potential Therapeutic Interventions,” Frontiers in Cell and Developmental Biology 11 (2023): 1275475.

[160] Nguyen T. K. H. and Kang H., “Reading M(6)A Marks in mRNA: A Potent Mechanism of Gene Regulation in Plants,” Journal of Integrative Plant Biology 66, no. 12 (2024): 2586–2599.

[161] Liu L., Li H., Hu D. et al., “Insights Into N6-methyladenosine and Programmed Cell Death in Cancer,” Molecular Cancer 21, no. 1 (2022): 32.

[162] Ma S., Chen C., Ji X. et al., “The Interplay Between m6A RNA Methylation and Noncoding RNA in Cancer,” Journal of Hematology & Oncology 12, no. 1 (2019): 121.

[163] Xue T., Liu X., Zhang M. et al., “PADI2-Catalyzed MEK1 Citrullination Activates ERK1/2 and Promotes IGF2BP1-Mediated SOX2 mRNA Stability in Endometrial Cancer,” Advanced Science (Weinh) 8, no. 6 (2021): 2002831.

[164] Chan F. F., Kwan K. K. L., and Seoung D. H., “N6-Methyladenosine Modification Activates the Serine Synthesis Pathway to Mediate Therapeutic Resistance in Liver Cancer,” Molecular Therapy 32, no. 12 (2024): 4435–4447. S1525-0016(24)00685-3.

[165] Rupareliya M. and Shende P., “Influence of RNA Methylation on Cancerous Cells: A Prospective Approach for Alteration of in Vivo Cellular Composition,” Advances in Experimental Medicine and Biology (2024),

[166] Chen H., Xuan A., Shi X. et al., “RNA N6-methyladenosine Modification in Arthritis: New Insights Into Pathogenesis,” Modern Rheumatology (2024): roae080.

[167] Tatsuno T. and Ishigaki Y., “Multiple Phosphorylations of SR Protein SRSF3 and Its Binding to mA Reader YTHDC1 in Human Cells,” Cells 11, no. 9 (2022): 1461.

[168] Rong H., Wang D., Wang Y., Dong C., and Wang G., “YTHDF1 in Tumor Cell Metabolism: An Updated Review,” Molecules (Basel, Switzerland) 29, no. 1 (2023): 140.

[169] Zhu L., Zhang H., Zhang X., and Xia L., “RNA m6A Methylation Regulators in sepsis,” Molecular and Cellular Biochemistry 479, no. 9 (2024): 2165–2180.

[170] Zhang L., Cai E., Xu Y. et al., “YTHDF1 facilitates Esophageal Cancer Progression via Augmenting m6A-dependent TINAGL1 Translation,” Cell Signalling 122 (2024): 111332.

[171] Shi Y., Yin L., Li J. Y. et al., “FTO Mediates Bisphenol F-induced Blood-testis Barrier Impairment Through Regulating Ferroptosis via YTHDF1/TfRc and YTHDF2/SLC7A11 Signal Axis,” Environmental Pollution 359 (2024): 124531.

[172] Li J., Chen K., Dong X. et al., “YTHDF1 promotes mRNA Degradation via YTHDF1-AGO2 Interaction and Phase Separation,” Cell Proliferation 55, no. 1 (2022): e13157.

[173] Wang X., Zhao B. S., Roundtree I. A. et al., “N(6)-methyladenosine Modulates Messenger RNA Translation Efficiency,” Cell 161, no. 6 (2015): 1388–1399.

[174] T. Kazuo, Yoshimura K., Inoue Y. et al., “YTHDF1 and YTHDF2 Are Associated With Better Patient Survival and an Inflamed Tumor-immune Microenvironment in Non-small-cell Lung Cancer,” Oncoimmunology 10, no. 1 (2021): 1962656.

[175] Zhu Z. M., Huo F. C., Zhang J. et al., “Crosstalk Between m6A Modification and Alternative Splicing During Cancer Progression,” Clinical and translational medicine 13, no. 10 (2023): e1460.

[176] Kolathur K. K., “Role of Promoters in Regulating Alternative Splicing,” Gene 782 (2021): 145523.

[177] Roundtree I. and He C., “Nuclear M(6)A Reader YTHDC1 Regulates mRNA Splicing,” Trends in Genetics 32, no. 6 (2016): 320–321.

[178] Roundtree I. A., Luo G. Z., Zhang Z. et al., “YTHDC1 mediates Nuclear Export of N-methyladenosine Methylated mRNAs,” Elife 6 (2017): e31311.

[179] Ramesh-Kumar D. and Guil S., “The IGF2BP family of RNA Binding Proteins Links Epitranscriptomics to Cancer,” Seminars in Cancer Biology 86, no. Pt 3 (2022): 18–31.

[180] Korn S. M., Ulshöfer C. J., Schneider T., and Schlundt A., “Structures and Target RNA Preferences of the RNA-binding Protein family of IGF2BPs: An Overview,” Structure (London, England) 29, no. 8 (2021): 787–803.

[181] Ying Y., Wu Y., Zhang F. et al., “Co-transcriptional R-loops-mediated Epigenetic Regulation Drives Growth Retardation and Docetaxel Chemosensitivity Enhancement in Advanced Prostate Cancer,” Molecular cancer 23, no. 1 (2024): 79.

[182] Elcheva I. A., Gowda C. P., Bogush D. et al., “IGF2BP family of RNA-binding Proteins Regulate Innate and Adaptive Immune Responses in Cancer Cells and Tumor Microenvironment,” Frontiers in immunology 14 (2023): 1224516.

[183] Safaei M., Sundararajan E. A., Driss M., Boulila W., and Shapi’i A., “A Systematic Literature Review on Obesity: Understanding the Causes & Consequences of Obesity and Reviewing Various Machine Learning Approaches Used to Predict Obesity,” Computers in Biology and Medicine 136 (2021): 104754.

[184] Yuan S., Chen J., Li X. et al., “Lifestyle and Metabolic Factors for Nonalcoholic Fatty Liver Disease: Mendelian Randomization Study,” European Journal of Epidemiology 37, no. 7 (2022): 723–733.

[185] Yip T. C. F., Vilar-Gomez E., Petta S. et al., “Geographical Similarity and Differences in the Burden and Genetic Predisposition of NAFLD,” Hepatology 77, no. 4 (2023): 1404–1427.

[186] Marios A. and Lowenstein C. J., “Dyslipidemia,” Annals of Internal Medicine 176, no. 6 (2023): ITC81–ITC96.

[187] Puengel T. and Tacke F., “Efruxifermin, an Investigational Treatment for Fibrotic or Cirrhotic Nonalcoholic Steatohepatitis (NASH),” Expert Opinion on Investigational Drugs 32, no. 6 (2023): 451–461.

[188] Meier J. J., “GLP-1 Receptor Agonists for Individualized Treatment of Type 2 Diabetes Mellitus,” Nature reviews Endocrinology 8, no. 12 (2012): 728–742.

[189] Qiu Y. Y., Zhang J., Zeng F. Y., and Zhu Y. Z., “Roles of the Peroxisome Proliferator-activated Receptors (PPARs) in the Pathogenesis of Nonalcoholic Fatty Liver Disease (NAFLD),” Pharmacological Research 192 (2023): 106786.

[190] Sirtori C. R., “The Pharmacology of Statins,” Pharmacological Research 88 (2014): 3–11.

[191] Perdomo C. M., Cohen R. V., Sumithran P., Clément K., and Frühbeck G., “Contemporary Medical, Device, and Surgical Therapies for Obesity in Adults,” Lancet 401, no. 10382 (2023): 1116–1130.

[192] Reid T. J. and Korner J., “Medical and Surgical Treatment of Obesity,” Medical Clinics of North America 106, no. 5 (2022): 837–852.

[193] Fink J., Seifert G., Blüher M., Fichtner-Feigl S., and Marjanovic G., “Obesity Surgery,” Dtsch Arztebl Int 119, no. 5 (2022): 70–80.

[194] Sun H., Lin W., Tang Y. et al., “Sustained Remission of Type 2 Diabetes in Rodents by Centrally Administered Fibroblast Growth Factor 4,” Cell metabolism 35, no. 6 (2023): 1022–1037.e6.

[195] Xu S., Wu X., Wang S. et al., “TRIM56 protects Against Nonalcoholic Fatty Liver Disease by Promoting the Degradation of Fatty Acid Synthase,” Journal of Clinical Investigation 134, no. 5 (2024): e166149.

[196] Wang Z., Ye M., Zhang X. J. et al., “Impact of NAFLD and Its Pharmacotherapy on Lipid Profile and CVD,” Atherosclerosis 355 (2022): 30–44.

[197] Augestad I. L., Pintana H., Larsson M. et al., “Regulation of Glycemia in the Recovery Phase after Stroke Counteracts the Detrimental Effect of Obesity-Induced Type 2 Diabetes on Neurological Recovery,” Diabetes 69, no. 9 (2020): 1961–1973.

[198] Falkevall A., Mehlem A., Folestad E. et al., “Inhibition of VEGF-B Signaling Prevents Non-alcoholic Fatty Liver Disease Development by Targeting Lipolysis in the White Adipose Tissue,” Journal of Hepatology 78, no. 5 (2023): 901–913.

[199] Zhang Y., Chen W., Zheng X. et al., “Regulatory Role and Mechanism of M(6)A RNA Modification in Human Metabolic Diseases,” Molecular Therapy – Oncolytics 22 (2021): 52–63.

[200] SantaCruz-Calvo S., Bharath L., Pugh G. et al., “Adaptive Immune Cells Shape Obesity-associated Type 2 Diabetes Mellitus and Less Prominent Comorbidities,” Nature Reviews Endocrinology 18, no. 1 (2022): 23–42.

[201] Loos R. J. F. and Yeo G. S. H., “The Genetics of Obesity: From Discovery to Biology,” Nature Reviews Genetics 23, no. 2 (2022): 120–133.

[202] Huang T., Song J., Gao J. et al., “Adipocyte-derived Kynurenine Promotes Obesity and Insulin Resistance by Activating the AhR/STAT3/IL-6 Signaling,” Nature Communications 13, no. 1 (2022): 3489.

[203] Müller T. D., Blüher M., Tschöp M. H., and DiMarchi R. D., “Anti-obesity Drug Discovery: Advances and Challenges,” Nature Reviews Drug Discovery 21, no. 3 (2022): 201–223.

[204] Münzker J., Haase N., Till A. et al., “Functional Changes of the Gastric Bypass Microbiota Reactivate Thermogenic Adipose Tissue and Systemic Glucose Control via Intestinal FXR-TGR5 Crosstalk in Diet-induced Obesity,” Microbiome 10, no. 1 (2022): 96.

[205] Li Z., Zhang B., Wang N., ZUo Z., Wei H., and Zhao F., “A Novel Peptide Protects Against Diet-induced Obesity by Suppressing Appetite and Modulating the Gut Microbiota,” Gut 72, no. 4 (2023): 686–698.

[206] Sun M. and Zhang X., “Epigenetic Regulation of N6-methyladenosine Modifications in Obesity,” Journal of Diabetes Investigation 12, no. 8 (2021): 1306–1315.

[207] Wu R., Chen Y., Liu Y. et al., “m6A methylation Promotes White-to-beige Fat Transition by Facilitating Hif1a Translation,” Embo Reports 22, no. 11 (2021): e52348.

[208] Chen Y., Wu R., Chen W. et al., “Curcumin Prevents Obesity by Targeting TRAF4-induced Ubiquitylation in M A-dependent Manner,” Embo Reports 22, no. 5 (2021): e52146.

[209] Yang Z., Yu G. L., Zhu X., Peng T. H., and Lv Y. C., “Critical Roles of FTO-mediated mRNA m6A Demethylation in Regulating Adipogenesis and Lipid Metabolism: Implications in Lipid Metabolic Disorders,” Genes & Diseases 9, no. 1 (2021): 51–61.

[210] Lan T., Yu Y., Zhang J. et al., “Cordycepin Ameliorates Nonalcoholic Steatohepatitis by Activation of the AMP-Activated Protein Kinase Signaling Pathway,” Hepatology 74, no. 2 (2021): 686–703.

[211] Luo Y., Li J. E., Zeng H., Zhang Y., Yang S., and Liu J., “Semaglutide Alleviates the Pancreatic β Cell Function via the METTL14 Signaling and Modulating Gut Microbiota in Type 2 Diabetes Mellitus Mice,” Life Sciences 361 (2025): 123328.

[212] Li Y. L., Li L., Liu Y. H., Hu L. K., and Yan Y. X., “Identification of Metabolism-Related Proteins as Biomarkers of Insulin Resistance and Potential Mechanisms of m6A Modification,” Nutrients 15, no. 8 (2023): 1839.

[213] Nabeel-Shah S., Pu S., Burke G. L. et al., “Recruitment of the mA/m6Am Demethylase FTO to Target RNAs by the Telomeric Zinc Finger Protein ZBTB48,” Genome biology 25, no. 1 (2024): 246.

[214] Xiao X., Jesus D. F. D., Ju C. W. et al., “m(6)A mRNA Methylation in Brown Fat Regulates Systemic Insulin Sensitivity via an Inter-organ Prostaglandin Signaling Axis Independent of UCP1,” Cell metabolism 36, no. 10 (2024): 2207–2227.e9.

[215] Chen C., Zhao M., Guo J., Kuang X., Chen Z., and Wang F., “Electrochemical Detection of FTO With N-kethoxal Labeling and MazF Cleavage,” RSC Advances 14, no. 35 (2024): 25561–25570.

[216] Wang X., Wu R., Liu Y. et al., “m(6)A mRNA Methylation Controls Autophagy and Adipogenesis by Targeting Atg5 and Atg7,” Autophagy 16, no. 7 (2020): 1221–1235.

[217] Wang L., Song C., Wang N. et al., “NADP Modulates RNA M(6)A Methylation and Adipogenesis via Enhancing FTO Activity,” Nature Chemical Biology 16, no. 12 (2020): 1394–1402.

[218] Azzam S. K., Alsafar H., and Sajini A. A., “FTO m6A Demethylase in Obesity and Cancer: Implications and Underlying Molecular Mechanisms,” International Journal of Molecular Sciences 23, no. 7 (2022): 3800.

[219] Qin Y., Li B., Arumugam S. et al., “m(6)A mRNA Methylation-directed Myeloid Cell Activation Controls Progression of NAFLD and Obesity,” Cell reports 37, no. 6 (2021): 109968.

[220] Laakso M., “Biomarkers for Type 2 Diabetes,” Mol Metab 27S, no. Suppl (2019): S139–S146.

[221] Srikanth V., Sinclair A. J., Hill-Briggs F., Moran C., and Biessels G. J., “Type 2 Diabetes and Cognitive Dysfunction-towards Effective Management of both Comorbidities,” The Lancet Diabetes & Endocrinology 8, no. 6 (2020): 535–545.

[222] Gloyn A. L. and Drucker D. J., “Precision Medicine in the Management of Type 2 Diabetes,” The Lancet Diabetes & Endocrinology 6, no. 11 (2018): 891–900.

[223] Chen M., Lin W., Yi J., and Zhao Z., “Exploring the Epigenetic Regulatory Role of m6A-Associated SNPs in Type 2 Diabetes Pathogenesis,” Pharmacogenomics and Personalized Medicine 14 (2021): 1369–1378.

[224] Yun J. S., Jung S. H., Shivakumar M. et al., “Polygenic Risk for Type 2 Diabetes, Lifestyle, Metabolic Health, and Cardiovascular Disease: A Prospective UK Biobank Study,” Cardiovascular Diabetology 21, no. 1 (2022): 131.

[225] Sweeting A., Wong J., Murphy H. R., and Ross G. P., “A Clinical Update on Gestational Diabetes Mellitus,” Endocrine Reviews 43, no. 5 (2022): 763–793.

[226] Samms R. J., Zhang G. F., He W. et al., “Tirzepatide Induces a Thermogenic-Like Amino Acid Signature in Brown Adipose Tissue,” Molecular Metabolism 64 (2022): 101550.

[227] Mirzadeh Z., Faber C. L., and Schwartz M. W., “Central Nervous System Control of Glucose Homeostasis: A Therapeutic Target for Type 2 Diabetes?,” Annual Review of Pharmacology and Toxicology 62 (2022): 55–84.

[228] Wang R. R., Qiu X., Pan R. et al., “Dietary Intervention Preserves β Cell Function in Mice Through CTCF-mediated Transcriptional Reprogramming,” Journal of Experimental Medicine 219, no. 7 (2022): e20211779.

[229] Park Y. M., Bookwalter D. B., O’Brien K. M., Jackson C. L., Weinberg C. R., and Sandler D. P., “A Prospective Study of Type 2 Diabetes, Metformin Use, and Risk of Breast Cancer,” Annals of Oncology 32, no. 3 (2021): 351–359.

[230] Nauck M. A., Wefers J., and Meier J. J., “Treatment of Type 2 Diabetes: Challenges, Hopes, and Anticipated Successes,” The Lancet Diabetes & Endocrinology 9, no. 8 (2021): 525–544.

[231] Lei L., Bai Y. H., Jiang H. Y., He T., Li M., and Wang J. P., “A Bioinformatics Analysis of the Contribution of m6A Methylation to the Occurrence of Diabetes Mellitus,” Endocrine Connections 10, no. 10 (2021): 1253–1265.

[232] Zhang H., Gu Y., Gang Q., Huang J., Xiao Q., and Ha X., “N6-methyladenosine RNA Modification: An Emerging Molecule in Type 2 Diabetes Metabolism,” Frontiers of Endocrinology (Lausanne) 14 (2023): 1166756.

[233] Li Y., Zhang Q., Cui G. et al., “m(6)A Regulates Liver Metabolic Disorders and Hepatogenous Diabetes,” Genomics, Proteomics & Bioinformatics 18, no. 4 (2020): 371–383.

[234] Li Y., Zhang D., Gao Y. et al., “METTL3 exacerbates Insulin Resistance in Hepatocytes by Regulating m6A Modification of Cytochrome P450 2B6,” Nutrition & Metabolism (Lond) 20, no. 1 (2023): 40.

[235] Zhou B., Liu C., Xu L. et al., “N6 - Methyladenosine Reader Protein YT521-B Homology Domain-Containing 2 Suppresses Liver Steatosis by Regulation of mRNA Stability of Lipogenic Genes,” Hepatology 73, no. 1 (2021): 91–103.

[236] Huang X., He W., Fan S., Li H., and Ye G., “IGF2BP3-mediated Enhanced Stability of MYLK Represses MSC Adipogenesis and Alleviates Obesity and Insulin Resistance in HFD Mice,” Cellular and Molecular Life Sciences 81, no. 1 (2024): 17.

[237] Ren Y., Li Z., Li J. et al., “m6A mRNA Methylation: Biological Features, Mechanisms, and Therapeutic Potentials in Type 2 Diabetes Mellitus,” Obesity Reviews 24, no. 12 (2023): e13639.

[238] Jiao Y., Williams A., and Wei N., “Quercetin Ameliorated Insulin Resistance via Regulating METTL3-mediated N6-methyladenosine Modification of PRKD2 mRNA in Skeletal Muscle and C2C12 Myocyte Cell Line,” Nutrition, Metabolism and Cardiovascular Diseases 32, no. 11 (2022): 2655–2668.

[239] Jiang L., Liu X., Hu X. et al., “METTL3-mediated mA Modification of TIMP2 mRNA Promotes Podocyte Injury in Diabetic Nephropathy,” Molecular Therapy 30, no. 4 (2022): 1721–1740.

[240] Chen X., Wang Y., Wang J. N. et al., “Lactylation-driven FTO Targets CDK2 to Aggravate Microvascular Anomalies in Diabetic Retinopathy,” EMBO Molecular Medicine 16, no. 2 (2024): 294–318.

[241] Xu Z., Jia K., Wang H. et al., “METTL14-regulated PI3K/Akt Signaling Pathway via PTEN Affects HDAC5-mediated Epithelial-mesenchymal Transition of Renal Tubular Cells in Diabetic Kidney Disease,” Cell Death & Disease 12, no. 1 (2021): 32.

[242] Li M., Deng L., and Xu G., “METTL14 promotes Glomerular Endothelial Cell Injury and Diabetic Nephropathy via m6A Modification of α-klotho,” Molecular Medicine 27, no. 1 (2021): 106.

[243] Meng L., Lin H., Huang X., Weng J., Peng F., and Wu S., “METTL14 suppresses Pyroptosis and Diabetic Cardiomyopathy by Downregulating TINCR lncRNA,” Cell Death & Disease 13, no. 1 (2022): 38.

[244] Yang Y., Shen F., Huang W. et al., “Glucose Is Involved in the Dynamic Regulation of m6A in Patients with Type 2 Diabetes,” Journal of Clinical Endocrinology and Metabolism 104, no. 3 (2019): 665–673.

[245] Xie W., Ma L. L., Xu Y. Q., Wang B. H., and Li S. M., “METTL3 inhibits Hepatic Insulin Sensitivity via N6-methyladenosine Modification of Fasn mRNA and Promoting Fatty Acid Metabolism,” Biochemical and Biophysical Research Communications 518, no. 1 (2019): 120–126.

[246] Jiang L., Liu X., Hu X. et al., “METTL3-mediated M(6)A Modification of TIMP2 mRNA Promotes Podocyte Injury in Diabetic Nephropathy,” Molecular Therapy 30, no. 4 (2022): 1721–1740.

[247] Li M., Deng L., and Xu G., “METTL14 promotes Glomerular Endothelial Cell Injury and Diabetic Nephropathy via m6A Modification of Alpha-klotho,” Molecular Medicine 27, no. 1 (2021): 106.

[248] Regué L., Zhao L., Ji F., Wang H., Avruch J., and Dai N., “RNA m6A Reader IMP2/IGF2BP2 Promotes Pancreatic Beta-cell Proliferation and Insulin Secretion by Enhancing PDX1 Expression,” Molecular Metabolism 48 (2021): 101209.

[249] Riazi K., Azhari H., Charette J. H. et al., “The Prevalence and Incidence of NAFLD Worldwide: A Systematic Review and Meta-analysis,” Lancet Gastroenterol Hepatol 7, no. 9 (2022): 851–861.

[250] Sumida Y. and Yoneda M., “Current and Future Pharmacological Therapies for NAFLD/NASH,” Journal of Gastroenterology 53, no. 3 (2018): 362–376.

[251] Younossi Z., Tacke F., Arrese M. et al., “Global Perspectives on Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis,” Hepatology 69, no. 6 (2019): 2672–2682.

[252] Cotter T. G., Rinella and M., “Rinella,” Gastroenterology 158, no. 7 (2020): 1851–1864.

[253] Llovet J. M., Willoughby C. E., Singal A. G. et al., “Nonalcoholic Steatohepatitis-related Hepatocellular Carcinoma: Pathogenesis and Treatment,” Nature reviews Gastroenterology & hepatology 20, no. 8 (2023): 487–503.

[254] Koning M., Herrema H., Nieuwdorp M., and Meijnikman A. S., “Targeting Nonalcoholic Fatty Liver Disease via Gut Microbiome-centered Therapies,” Gut Microbes 15, no. 1 (2023): 2226922.

[255] Younossi Z., Anstee Q. M., Marietti M. et al., “Global Burden of NAFLD and NASH: Trends, Predictions, Risk Factors and Prevention,” Nature Reviews Gastroenterology & Hepatology 15, no. 1 (2018): 11–20.

[256] Huang D. Q., El-Serag H. B., and Loomba R., “Global Epidemiology of NAFLD-related HCC: Trends, Predictions, Risk Factors and Prevention,” Nature Reviews Gastroenterology & Hepatology 18, no. 4 (2021): 223–238.

[257] Alves-Bezerra M. and Cohen D. E., “Triglyceride Metabolism in the Liver,” Comprehensive Physiology 8, no. 1 (2017): 1–8.

[258] Qin Y., Li B., Arumugam S. et al., “m(6)A mRNA Methylation-directed Myeloid Cell Activation Controls Progression of NAFLD and Obesity,” Cell reports 37, no. 6 (2021): 109968.

[259] Yang Y., Cai J., Yang X. et al., “Dysregulated m6A Modification Promotes Lipogenesis and Development of Non-alcoholic Fatty Liver Disease and Hepatocellular Carcinoma,” Molecular Therapy 30, no. 6 (2022): 2342–2353.

[260] Jiang T., Xiao Y., Zhou J. et al., “Arbutin Alleviates Fatty Liver by Inhibiting Ferroptosis via FTO/SLC7A11 Pathway,” Redox Biology 68 (2023): 102963.

[261] Zhu X., Tang H., Yang M., and Yin K., “N6-methyladenosine in Macrophage Function: A Novel Target for Metabolic Diseases,” Trends in Endocrinology and Metabolism 34, no. 2 (2023): 66–84.

[262] Kang Q., Zhu X., Ren D. et al., “Adipose METTL14-Elicited N - Methyladenosine Promotes Obesity, Insulin Resistance, and NAFLD through Suppressing β Adrenergic Signaling and Lipolysis,” Advanced Science (Weinh) 10, no. 28 (2023): e2301645.

[263] Tang J., Zhao X., Wei W. et al., “METTL16-mediated Translation of CIDEA Promotes Non-alcoholic Fatty Liver Disease Progression via m6A-dependent Manner,” PeerJ 10 (2022): e14379.

[264] Ming X., Chen S., Li H., Wang Y., Zhou L., and Lv Y., “m6A RNA Methylation and Implications for Hepatic Lipid Metabolism,” Dna and Cell Biology 43, no. 6 (2024 Jun): 271–278.

[265] Wu J., Pan J., Zhou W., Ji G., and Dang Y., “The Role of N6-methyladenosine in Macrophage Polarization: A Novel Treatment Strategy for Non-alcoholic Steatohepatitis,” Biomedicine & Pharmacotherapy 171 (2024): 116145.

[266] Kang H., Zhang Z., Yu L., Li Y., Liang M., and Zhou L., “FTO Reduces Mitochondria and Promotes Hepatic Fat Accumulation Through RNA Demethylation,” Journal of Cellular Biochemistry 119, no. 7 (2018): 5676–5685.

[267] Tang Z., Sun C., Yan Y. et al., “Aberrant Elevation of FTO Levels Promotes Liver Steatosis by Decreasing the m6A Methylation and Increasing the Stability of SREBF1 and ChREBP mRNAs,” Journal of Molecular Cell Biology 14, no. 9 (2023): mjac061.

[268] Yang Z., Yu G. L., Zhu X., Peng T. H., and Lv Y. C., “Critical Roles of FTO-mediated mRNA m6A Demethylation in Regulating Adipogenesis and Lipid Metabolism: Implications in Lipid Metabolic Disorders,” Genes & Diseases 9, no. 1 (2021): 51–61.

[269] Hu Y., Feng Y., Zhang L. et al., “GR-mediated FTO Transactivation Induces Lipid Accumulation in Hepatocytes via Demethylation of M(6)A on Lipogenic mRNAs,” RNA Biology 17, no. 7 (2020): 930–942.

[270] Peng Z., Gong Y., Wang X. et al., “METTL3-m(6)A-Rubicon Axis Inhibits Autophagy in Nonalcoholic Fatty Liver Disease,” Molecular Therapy 30, no. 2 (2022): 932–946.

[271] Zhou B., Liu C., Xu L. et al., “N6-methyladenosine Reader Protein Ythdc2 Suppresses Liver Steatosis via Regulation of mRNA Stability of Lipogenic Genes,” Hepatology 73, no. 1 (2021): 91–103.

[272] Luo P., Li S., Jing W., Tu J., and Long X., “N6-methyladenosine RNA Modification in Nonalcoholic Fatty Liver Disease,” Trends in Endocrinology and Metabolism 34, no. 12 (2023): 838–848.

[273] Zhu X., Tang H., Yang M., and Yin K., “N6-methyladenosine in Macrophage Function: A Novel Target for Metabolic Diseases,” Trends in Endocrinology and Metabolism 34, no. 2 (2023): 66–84.

[274] Dang Y., Xu J., Yang Y. et al., “Ling-gui-zhu-gan Decoction Alleviates Hepatic Steatosis Through SOCS2 Modification by N6-methyladenosine,” Biomedicine & Pharmacotherapy 127 (2020): 109976.

[275] Xie W., Ma L. L., Xu Y. Q., Wang B. H., and Li S. M., “METTL3 inhibits Hepatic Insulin Sensitivity via N6-methyladenosine Modification of Fasn mRNA and Promoting Fatty Acid Metabolism,” Biochemical and Biophysical Research Communications 518, no. 1 (2019): 120–126.

[276] Ni W. J., Zhou H., Lu H. et al., “Genetic and Pharmacological Inhibition of METTL3 Alleviates Renal Fibrosis by Reducing EVL m6A Modification Through an IGF2BP2-dependent Mechanism,” Clinical and translational medicine 13, no. 8 (2023): e1359.

[277] Wang F., Bai J., Zhang X. et al., “METTL3/YTHDF2 m6A axis Mediates the Progression of Diabetic Nephropathy Through Epigenetically Suppressing PINK1 and Mitophagy,” Journal of Diabetes Investigation 15, no. 3 (2024): 288–299.

[278] Xu H., Lin C., Yang J. et al., “The Role of N(6)-Methyladenosine in Inflammatory Diseases,” Oxidative Medicine and Cellular Longevity 2022 (2022): 9744771.

[279] Yin S., Li W., Wang J., Wu H., Hu J., and Feng Y., “Screening of Key Genes Associated With m6A Methylation in Diabetic Nephropathy Patients by CIBERSORT and Weighted Gene Coexpression Network Analysis,” American Journal of Translational Research 14, no. 4 (2022): 2280–2290.

[280] Dong S., Zhang J., Fu Y. et al., “METTL3-mediated m6A Modification of SIRT1 mRNA Affects the Progression of Diabetic Cataracts Through Cellular Autophagy and Senescence,” Journal of Translational Medicine 22, no. 1 (2024): 865.

[281] Liu K., He X., Huang J. et al., “Short-chain Fatty Acid-butyric Acid Ameliorates Granulosa Cells Inflammation Through Regulating METTL3-mediated N6-methyladenosine Modification of FOSL2 in Polycystic Ovarian Syndrome,” Clinical Epigenetics 15, no. 1 (2023): 86.

[282] Onalan E., Yakar B., Onalan E. E., Karakulak K., Kaymaz T., and Donder E., “m(6)A RNA, FTO, ALKBH5 Expression in Type 2 Diabetic and Obesity Patients,” Journal of the College of Physicians and Surgeons–Pakistan 32, no. 9 (2022): 1143–1148.

[283] Ling C., “Epigenetic Regulation of Insulin Action and Secretion—role in the Pathogenesis of Type 2 Diabetes,” Journal of Internal Medicine 288, no. 2 (2020): 158–167.

[284] Velazquez-Roman J., Angulo-Zamudio U. A., León-Sicairos N. et al., “Association of FTO, ABCA1, ADRB3, and PPARG Variants With Obesity, Type 2 Diabetes, and Metabolic Syndrome in a Northwest Mexican Adult Population,” Journal of Diabetes and Its Complications 35, no. 11 (2021): 108025.

[285] Li Y. L., Zhang Y., Chen N., and Yan Y. X., “The Role of M(6)A Modification in Type 2 Diabetes: A Systematic Review and Integrative Analysis,” Gene 898 (2024): 148130.

[286] Wan S. J., Hua Q., Xing Y. J. et al., “Decreased Urine N6-methyladenosine Level Is Closely Associated With the Presence of Diabetic Nephropathy in Type 2 Diabetes Mellitus,” Frontiers of Endocrinology (Lausanne) 13 (2022): 986419.

[287] Pan Y., Chen H., Zhang X. et al., “METTL3 drives NAFLD-related Hepatocellular Carcinoma and Is a Therapeutic Target for Boosting Immunotherapy,” Cell Reports Medicine 4, no. 8 (2023): 101144.

[288] Zhang W., Zhang S., Dong C. et al., “A Bibliometric Analysis of RNA Methylation in Diabetes Mellitus and Its Complications From 2002 to 2022,” Frontiers of Endocrinology (Lausanne) 13 (2022): 997034.

[289] Xiao L., De Jesus D. F., Ju C. W. et al., “Divergent Roles of mA in Orchestrating Brown and White Adipocyte Transcriptomes and Systemic Metabolism,” Nature Communications 16, no. 1 (2025): 533.

[290] Wang J, Chen L, Qiang P. The role of IGF2BP2, an m6A reader gene, in human metabolic diseases and cancers. Cancer Cell International 21, no. 1 (2021): 99.

[291] Zhang B, Jiang H, Dong Z, Sun A, Ge J. The critical roles of m6A modification in metabolic abnormality and cardiovascular diseases. Genes & Diseases 8, no. 6 (2020): 746-758.

[292] Huang H, Weng H, Chen J. m(6)A Modification in Coding and Non-coding RNAs: Roles and Therapeutic Implications in Cancer. Cancer Cell. 37, no. 3 (2020): 270-288.

[293] Deng L. J., Deng W. Q., Fan S. R. et al. m6A modification: Recent Advances, Anticancer Targeted Drug Discovery and Beyond. Molecular Cancer 21, no. 1 (2022): 52.

[294] Pomaville M. M. and He C. Advances in Targeting RNA Modifications for Anticancer Therapy. Trends in Cancer 9, no. 7 (2023): 528–542.

[295] Haruehanroengra P., Zheng Y. Y., Zhou Y., Huang Y., and Sheng J. RNA Modifications and Cancer. RNA Biol 17, no. 11 (2020): 1560–1575.

[296] Zhao T., Wang J., Wu Y. et al., “Increased m6A Modification of RNA Methylation Related to the Inhibition of Demethylase FTO Contributes to MEHP-induced Leydig Cell Injury,” Environmental Pollution 268, no. Pt A (2021): 115627.

[297] Zhong H., Tang H. F., and Kai Y., “N6-methyladenine RNA Modification (mA): An Emerging Regulator of Metabolic Diseases,” Current Drug Targets 21, no. 11 (2020): 1056–1067.

[298] Wang Y. and Jia G., “Detection Methods of Epitranscriptomic Mark N6-methyladenosine,” Essays in Biochemistry 64, no. 6 (2020): 967–979.

[299] Tang J., Yu Z., Xia J. et al., “METTL14-Mediated m6A Modification of TNFAIP3 Involved in Inflammation in Patients with Active Rheumatoid Arthritis,” Arthritis Rheumatol 75, no. 12 (2023): 2116–2129.

[300] Sendinc E. and Shi Y., “RNA m6A Methylation Across the Transcriptome,” Molecular Cell 83, no. 3 (2023): 428–441.

[301] Xiong J., He J., Zhu J. et al., “Lactylation-Driven METTL3-Mediated RNA M(6)A Modification Promotes Immunosuppression of Tumor-infiltrating Myeloid Cells,” Molecular Cell 82, no. 9 (2022): 1660–1677.e10.

[302] Wang J. N., Wang F., Ke J. et al., “Inhibition of METTL3 Attenuates Renal Injury and Inflammation by Alleviating TAB3 m6A Modifications via IGF2BP2-dependent Mechanisms,” Science Translational Medicine 14, no. 640 (2022): eabk2709.

[303] Zhuang H., Yu B., Tao D. et al., “The Role of m6A Methylation in Therapy Resistance in Cancer,” Molecular Cancer 22, no. 1 (2023): 91.

[304] Yue S. W., Liu H. L., Su H. F. et al., “m6A-regulated Tumor Glycolysis: New Advances in Epigenetics and Metabolism,” Molecular Cancer 22, no. 1 (2023): 137.

[305] Lin H., Wang Y., Wang P., Long F., and Wang T., “Mutual Regulation Between N6-methyladenosine (m6A) Modification and Circular RNAs in Cancer: Impacts on Therapeutic Resistance,” Molecular Cancer 21, no. 1 (2022): 148.

[306] Ma W. and Wu T., “RNA m6A Modification in Liver Biology and Its Implication in Hepatic Diseases and Carcinogenesis,” American Journal of Physiology. Cell Physiology 323, no. 4 (2022): C1190–C1205.

[307] Yang L., Tian S., Zheng X. et al., “N6-methyladenosine RNA Methylation in Liver Diseases: From Mechanism to Treatment,” Journal of Gastroenterology 58, no. 8 (2023): 718–733.

[308] Hong Y. G., Yang Z., Chen Y. et al., “The RNA m6A Reader YTHDF1 Is Required for Acute Myeloid Leukemia Progression,” Cancer Research 83, no. 6 (2023): 845–860.

[309] Han X., Guo J., and Fan Z., “Interactions Between m6A Modification and miRNAs in Malignant Tumors,” Cell Death & Disease 12, no. 6 (2021): 598.

[310] Liang J., Liu X., Hu X. et al., “METTL3-mediated M(6)A Modification of TIMP2 mRNA Promotes Podocyte Injury in Diabetic Nephropathy,” Molecular Therapy 30, no. 4 (2022): 1721–1740.

[311] Zeng C., Huang W., Li Y., and Weng H., “Roles of METTL3 in Cancer: Mechanisms and Therapeutic Targeting,” Journal of Hematology & Oncology 13, no. 1 (2020): 117.

[312] Oerum S., Meynier V., Catala M., and Tisné C., “A Comprehensive Review of m6A/m6Am RNA Methyltransferase Structures,” Nucleic Acids Research 49, no. 13 (2021): 7239–7255.

[313] Yankova E., Blackaby W., Albertella M. et al., “Small-molecule Inhibition of METTL3 as a Strategy Against Myeloid Leukaemia,” Nature 593, no. 7860 (2021): 597–601.

[314] Wang T., Kong S., Tao M., and Ju S., “The Potential Role of RNA N6-methyladenosine in Cancer Progression,” Molecular Cancer 19, no. 1 (2020): 88.

[315] Yan L. and Guo L., “The Role and Mechanism of m6A Methylation in Diabetic Nephropathy,” Life Sciences 363 (2025): 123355.

[316] Li C. Y., Su F., Liang Z. et al., “Macrophage M1 Regulatory Diabetic Nephropathy Is Mediated by m6A Methylation Modification of lncRNA Expression,” Molecular Immunology 144 (2022): 16–25.

[317] Li Z., Lao Y., Yan R., Li F., Guan X., and Dong Z., “N6-methyladenosine in Inflammatory Diseases: Important Actors and Regulatory Targets,” Gene 936 (2025): 149125.

[318] Feng S., Zhang Q., Liu Q. et al., “N 6-Methyladenosine Demethylase FTO Controls Macrophage Homeostasis in Diabetic Vasculopathy,” Diabetes 74, no. 1 (2025): 82–95.

[319] Liu Y., Zhang S., Liu K., Gu X., and Hu X., “RNA Modification and Digestive Tract Tumors: A Review,” Current Medicinal Chemistry (2025),

[320] Shi K., Sa R., Dou L. et al., “METTL3 exerts Synergistic Effects on m6A Methylation and Histone Modification to Regulate the Function of VGF in Lung Adenocarcinoma,” Clin Epigenetics 15, no. 1 (2023): 153.

[321] Lu C., Zhao H., Liu Y. et al., “Novel Role of the SIRT1 in Endocrine and Metabolic Diseases,” International Journal of Biological Science 19, no. 2 (2023): 484–501.

[322] Tanase D. M., Gosav E. M., Costea C. F. et al., “The Intricate Relationship Between Type 2 Diabetes Mellitus (T2DM), Insulin Resistance (IR), and Nonalcoholic Fatty Liver Disease (NAFLD),” Journal of Diabetes Research 2020 (2020): 3920196.

[323] Ferguson D. and Finck B. N., “Emerging Therapeutic Approaches for the Treatment of NAFLD and Type 2 Diabetes Mellitus,” Nature Reviews Endocrinology 17, no. 8 (2021): 484–495.

[324] Canfora E. E., Meex R. C. R., Venema K., and Blaak E. E., “Gut Microbial Metabolites in Obesity, NAFLD and T2DM,” Nature Reviews Endocrinology 15, no. 5 (2019): 261–273.

[325] Tillman E. J. and Rolph T., “FGF21: An Emerging Therapeutic Target for Non-Alcoholic Steatohepatitis and Related Metabolic Diseases,” Frontiers of Endocrinology (Lausanne) 11 (2020): 601290.

[326] Wang Y., Li L., Li J. et al., “The Emerging Role of m6A Modification in Regulating the Immune System and Autoimmune Diseases,” Frontiers in Cell and Developmental Biology 9 (2021): 755691.

[327] Qin W., Ding Y., Zhang W. et al., “Small Molecule-driven LKB1 Deacetylation Is Responsible for the Inhibition of Hepatic Lipid Response in NAFLD,” Journal of Lipid Research (2025): 100740.

RIGHTS & PERMISSIONS

2025 The Author(s). MedComm published by Sichuan International Medical Exchange & Promotion Association (SCIMEA) and John Wiley & Sons Australia, Ltd.